Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome

References

• Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016. DOI:10.1053/j.gastro.2016.02.031
   Web of Science ®Google Scholar
• Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. DOI:10.1038/nrdp.2016.14
   PubMed Web of Science ®Google Scholar
• Bellini M, Gambaccini D, Stasi C, et al. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014;20:8807–8820. DOI:10.3748/wjg.v20.i27.8807
   PubMed Web of Science ®Google Scholar
• Layer P, Stanghellini V. Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014;39:371–384. DOI:10.1111/apt.12604
   PubMed Web of Science ®Google Scholar
• Noble F, Wank SA, Crawley JN, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev. 1999;51:745–781.
   PubMed Web of Science ®Google Scholar
• Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides. 1994;15:731–755. DOI:10.1016/0196-9781(94)90104-x
   PubMed Web of Science ®Google Scholar
• Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001;96: 1499–1506. DOI:10.1111/j.1572-0241.2001.03804.x
   PubMed Web of Science ®Google Scholar
• Simren M, Abrahamsson H, Bjornsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut. 2001;48:20–27.
   PubMed Web of Science ®Google Scholar
• Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol. 2003;56:362–369.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–26. DOI:10.1038/ajg.2014.187
   PubMed Web of Science ®Google Scholar
• Serra J, Mascort-Roca J, Marzo-Castillejo M, et al. Clinical practice guidelines for the management of constipation in adults. Part 2: diagnosis and treatment. Gastroenterol Hepatol. 2016. DOI:10.1016/j.gastrohep.2016.02.007
   Google Scholar
• Mearin F, Ciriza C, Minguez M, et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108: 332–363. DOI:10.17235/reed.2016.4389/2016
   PubMed Web of Science ®Google Scholar
• Serra J, Azpiroz F, Malagelada JR. Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiology-Gastrointestinal Liver Physiol. 2001;281:G138–G143.
   Google Scholar
• Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15:355–361.
   PubMed Web of Science ®Google Scholar
• Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;CD003460. DOI:10.1002/14651858.CD003460.pub3
   Google Scholar
• Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58: 367–378. DOI:10.1136/gut.2008.163162
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109: 1350–1365. DOI:10.1038/ajg.2014.148
   PubMed Web of Science ®Google Scholar
• Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013;37: 49–61. DOI:10.1111/apt.12123
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107: 1714–1724. DOI:10.1038/ajg.2012.255
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107: 1702–1712. DOI:10.1038/ajg.2012.254
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29: 329–341. DOI:10.1111/j.1365-2036.2008.03881.x
   PubMed Web of Science ®Google Scholar
• Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104: 1831–1843. DOI:10.1038/ajg.2009.223
   PubMed Web of Science ®Google Scholar
• Chey WD, Pare P, Viegas A, et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol. 2008;103: 1217–1225. DOI:10.1111/j.1572-0241.2008.01808.x
   PubMed Web of Science ®Google Scholar
• Tack J, Van OM, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58: 357–365. DOI:10.1136/gut.2008.162404
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29: 315–328. DOI:10.1111/j.1365-2036.2008.03884.x
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358: 2344–2354. DOI:10.1056/NEJMoa0800670
   PubMed Web of Science ®Google Scholar
• Varga G, Balint A, Burghardt B, et al. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol. 2004;141:1275–1284. DOI:10.1038/sj.bjp.0705769.
   PubMed Web of Science ®Google Scholar
• Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev. 2003;23:559–605. DOI:10.1002/med.10042
   PubMed Web of Science ®Google Scholar
• Varga G. Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs. 2002;3:621–626.
   PubMedGoogle Scholar
• Maselli MA, Mennuni L. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterol Dietol. 2003;49:211–216.
   PubMedGoogle Scholar
• Scarpignato C, Kisfalvi I, D’Amato M, et al. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996;10:411–419.
   PubMed Web of Science ®Google Scholar
• Lal S, McLaughlin J, Barlow J, et al. Cholecystokinin pathways modulate sensations induced by gastric distension in humans. Am J Physiol Gastrointest Liver Physiol. 2004;287: G72–G79. DOI:10.1152/ajpgi.00351.2003
   PubMed Web of Science ®Google Scholar
• Feinle C, Meier O, Otto B, et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut. 2001;48:347–355.
   PubMed Web of Science ®Google Scholar
• Feinle C, D’Amato M, Read NW. Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Gastroenterology. 1996;110:1379–1385.
   PubMed Web of Science ®Google Scholar
• Meier R, D’Amato M, Pullwitt A, et al. Effect of a CCK-A receptor antagonist in an experimental model of delayed colonic transit time in man. Gastroenterology. 1994;106:A538.
   Google Scholar
• Persiani S, D’Amato M, Makovec F, et al. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther. 2002;40:198–206. doi:10.5414/cpp40198.
   PubMed Web of Science ®Google Scholar
• Webber C, Roth A, Persiani S, et al. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica. 2003;33: 625–641. DOI:10.1080/0049825031000089137
   PubMed Web of Science ®Google Scholar
• Persiani S, D’Amato M, Jakate A, et al. Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45:1177–1188. DOI:10.2165/00003088-200645120-00003.
   PubMed Web of Science ®Google Scholar
• D’Amato M, Whorwell PJ, Thompson DG, et al. The CCK-1 receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:S31.
   Google Scholar
• D’Amato M, Whorwell P, Thompson DG, et al. The efficacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut. 1999;45(Suppl 5):A258.
   Google Scholar
• Cremonini F, Camilleri M, McKinzie S, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol. 2005;100:652–663. DOI:10.1111/j.1572-0241.2005.41081.x.
   PubMed Web of Science ®Google Scholar
• Lobo B, Serra J, D’Amato M, et al. Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders. J Gastroenterol Hepatol. 2016;31:288–293. DOI:10.1111/jgh.13177.
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Pace F, D’Amato M, et al. A phase III, 6-month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK-1 antagonist dexloxiglumide in constipation-predominant IBS: the darwin study. Gastroenterology. 2008;134 (Suppl II):A157.
   Google Scholar
• Nusrat S, Miner PB Jr. New pharmacological treatment options for irritable bowel syndrome with constipation. Expert Opin Emerg Drugs. 2015;20:625–636. DOI:10.1517/14728214.2015.1105215
   PubMed Web of Science ®Google Scholar
• Pharmabiz. Forest to discontinue development in U.S. of dexloxiglumide for irritable bowel syndrome. Pharmabiz.com; 2003. Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=18155&sid=2
   Google Scholar
• Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150:1257–1261. DOI:10.1053/j.gastro.2016.03.035
   PubMed Web of Science ®Google Scholar
• Quigley EM. Commentary: long-term lubiprostone for constipation predominant IBS. Aliment Pharmacol Ther. 2012;35:962–963. DOI:10.1111/j.1365-2036.2012.05041.x
   PubMed Web of Science ®Google Scholar